ClinicalTrials.gg
RecruitingNCT07855510Updated Nov 6, 2026

A Clinical Trial of V175 and V175A in Healthy Adults

A Phase 1 interventional study of V175 and V175A in Lower Respiratory Tract Infection, sponsored by Merck Sharp & Dohme LLC. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Prevention

Updated Nov 6, 2026Now RecruitingFirst site in Australia+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
564
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Study summary

Researchers are looking for new vaccines to prevent lower respiratory tract infections. A lower respiratory tract infection is an infection in the lower part of the airways and/or the lungs. Respiratory syncytial virus (RSV), amongst other respiratory viruses, can cause these infections.

This trial will look at the RSV multivalent vaccines V175 and V175A in healthy participants. The goal of the trial is to learn about the safety of V175 and V175A and if participants tolerate them.

02

Conditions studied

  • Lower Respiratory Tract Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Is in good health
  • Is an individual of any sex/gender, from 18 years to 49 years of age inclusive, or 60 years to 84 years of age inclusive
  • Has a between 18 and 35 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a history of cancer ()
  • Has any known or suspected disease or condition, acquired or congenital
  • Has a history of Guillain-Barré Syndrome
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
564 participants (estimated)

Study arms

  • Experimental
    V175

    Participants will receive a single intramuscular (IM) vaccination of V175 on Day 1.

    Biological: V175

  • Experimental
    V175A

    Participants will receive a single IM vaccination of V175A on Day 1.

    Biological: V175A

  • Active comparator
    Control Vaccine

    Participants will receive a single IM vaccination of control vaccine on Day 1.

    Biological: Control Vaccine

  • Placebo comparator
    Placebo

    Participants will receive a single IM vaccination of placebo on Day 1.

    Other: Placebo

Interventions

  • BiologicalV175

    Intramuscular administration

  • BiologicalV175A

    Intramuscular administration

  • BiologicalControl Vaccine

    Intramuscular administration

  • OtherPlacebo

    Intramuscular administration

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Immediate Reactions After Vaccination

    The percentage of participants with immediate reactions after vaccination will be reported.

    Time frame: Up to approximately 30 minutes after vaccination

  2. Percentage of Participants With a Solicited Injection-Site Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with a solicited injection-site AE (ie, pre-listed in the participant's diary) will be reported.

    Time frame: Up to approximately 7 days after vaccination

  3. Percentage of Participants With a Solicited Systemic Adverse Event

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The percentage of participants with a solicited systemic AE (ie, pre-listed in the participant's diary) will be reported.

    Time frame: Up to approximately 7 days after vaccination

  4. Percentage of Participants With an Unsolicited Adverse Event

    An unsolicited AE is an AE that was not solicited using a vaccination report card and that is communicated by a participant (or their legally acceptable representative, if applicable). Unsolicited AEs include serious and nonserious AEs. The percentage of participants with an unsolicited adverse event will be reported.

    Time frame: Up to approximately 28 days after vaccination

  5. Percentage of Participants With a Serious Adverse Event (SAE)

    An SAE is defined as any untoward medical occurrence that at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. The percentage of participants with a SAE will be reported.

    Time frame: Up to approximately 12 months after vaccination

  6. Percentage of Participants With a Medically Attended Adverse Event (MAAE)

    MAAEs are defined as adverse events in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency department visit, office visit, or an urgent care visit with any medical personnel for any reason. The percentage of participants with a MAAE will be reported.

    Time frame: Up to approximately 12 months after vaccination

  7. Percentage of Participants With an Adverse Event of Special Interest (AESI) Including Potential Immune-Mediated Diseases (pIMDs)

    AESIs are selected serious and nonserious AEs which include but are not limited to pIMDs defined as a subset of AEs that includes both: established autoimmune disease(s) and inflammatory and/or neurologic disorder(s), which might or might not have an autoimmune etiology. The percentage of participants with an AESI will be reported.

    Time frame: Up to approximately 12 months after vaccination

Secondary outcomes

  1. Geometric Mean Ratio (GMR) of Anti-Respiratory Syncytial Virus-A (RSV-A) Neutralizing Antibodies Elicited by V175/V175A Relative to Control Vaccine

    Titers of Anti-RSV-A Neutralizing Antibody will be measured via the virus reduction neutralization test. GMR of Anti-Respiratory Syncytial Virus-A (RSV-A) Neutralizing Antibodies Elicited by V175/V175A relative to control vaccine will be reported.

    Time frame: Up to approximately 28 days after vaccination

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Aug 2028, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Oct 21, 2026
Primary completionEst.
Aug 8, 2028
CompletionEst.
Aug 8, 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
2 sites added — first site in Australia
Show 2 added (2 Australia)
  • Nucleus Network ( Site 0002) · Brisbane, Australia
  • Nucleus Network ( Site 0001) · Melbourne, Australia
Nov 6, 2026
Start date
Oct 27, 2026→Oct 21, 2026 (actual)
Nov 6, 2026
Contact
Study contact now listed: added T•••@msd.com · •••8839. See the current contact
Nov 6, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in Australia
    Show 2 added (2 Australia)
    • Nucleus Network ( Site 0002) · Brisbane, Australia
    • Nucleus Network ( Site 0001) · Melbourne, Australia
    Start date Oct 27, 2026→Oct 21, 2026 (now actual)
    Contact Study contact now listed: added T•••@msd.com · •••8839. See the current contact
    + 1 other change: verification date
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855510
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 21, 2026
Primary completion
Aug 8, 2028 (estimated)
Completion
Aug 8, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion